These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28231738)

  • 21. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.
    Njoroge SW; Burgess KR; Cobleigh MA; Alnajar HH; Gattuso P; Usha L
    Breast Cancer Res Treat; 2017 Nov; 166(1):315-319. PubMed ID: 28702897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
    Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
    Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
    Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D
    Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Guindalini RS; Song A; Fackenthal JD; Olopade OI; Huo D
    Cancer; 2016 Jun; 122(12):1913-20. PubMed ID: 26992017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
    Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
    Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
    Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
    Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
    Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
    Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
    Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.